Abstract
Abstract Ten years after the revolutionary work of Kohler and Milstein 1 clinical trials in lung cancer employing monoclonal antibodies are just beginning 2 . Clinical investigators are familiar with the critical issues in the design of clinical trials of chemotherapy. The design of monoclonal antibody trials will borrow heavily from that experience and yet will break new ground. In this review we will consider the issues governing the development of clinical trials strategies.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call